The Metabolic Health Index Identifies Patients That Will Benefit From Metabolic Surgery

J Surg Res. 2023 May:285:211-219. doi: 10.1016/j.jss.2022.10.044. Epub 2023 Jan 23.

Abstract

Introduction: Metabolic syndrome is a modern world's major health hazard related to comorbidities like type 2 diabetes and cardiovascular disease. Bariatric surgery is well known to lower this health risk in patients with obesity. There is a need for an objective measure to assess the intended reduction in health hazard and indirectly the eligibility for bariatric surgery. The Metabolic Health Index (MHI) quantitatively summarizes the cumulative impact of the metabolic syndrome on health status on a scale from 1 to 6. This study describes the use of the MHI as a supportive tool in the decision for and outcome assessment of bariatric surgery.

Methods: The general usability of the MHI was tested by extending its application to patient data of five other bariatric centers in the Netherlands. Retrospective laboratory and national bariatric quality registry data of 11,501 patients were collected.

Results: The quantification of (improvement in) metabolic health burden as measured by the MHI was independent of the dataset that was used to derive the MHI model. Patients with MHI > 2.8 prior to surgery improved significantly more in MHI 12 mo after surgery compared to patients with MHI ≤ 2.8 (1.1 compared to 0.4 MHI points, respectively; P < 0.001).

Conclusions: The MHI is robust between centers and is suitable for general use in clinical decision-making. As changes in MHI over time reflect metabolic health alterations, it is suitable as an outcome measure of surgery. An MHI cut-off value of 2.8 helps to predict the likelihood of significant improvement after surgery, independent of body mass index and known metabolic comorbidities.

Keywords: Bariatric surgery; Big data; Eligibility; Metabolic surgery; Metabolic syndrome; Outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bariatric Surgery*
  • Diabetes Mellitus, Type 2*
  • Humans
  • Metabolic Syndrome*
  • Obesity / surgery
  • Obesity, Morbid* / surgery
  • Retrospective Studies
  • Treatment Outcome